Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064150 · ClinicalTrials.gov registry record
Neuroendocrine Tumors - Patient Reported Outcomes
A clinical trial of Neuroendocrine Tumors and Neuroendocrine Carcinoma, sponsored by University of Iowa.
- Active
- Registry status
- 2,539
- Enrollment target
- 14
- Study locations
NCT05064150 is a study of Neuroendocrine Tumors and Neuroendocrine Carcinoma that is active but no longer recruiting, run by University of Iowa. The registered enrollment target is 2,539 participants, above the 131-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (1838% higher). The trial reports 14 study locations across 13 states.
The verdict
NCT05064150, a study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by University of Iowa.
- ACTIVE NOT RECRUITING
- Registry status
- 2,539 participants
- Enrollment target
- 14
- Study locations
Study Summary
With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for neuroendocrine tumors (NET) patients. We will conduct a study of all newly occurring GEP-NET and lung NET cases aged 18 years and older diagnosed between 01/01/2018 through 09/30/2024 across 14 sites participating in the National Patient-Centered Clinical Research Network (PCORnet), enrolling an average of 215 patients per site over the 3 year study period (2515 patients total), allowing up to 60 months of follow-up for medical record outcomes. Participants will complete four online or paper surveys over 18 months; these surveys will focus on patient-reported outcomes, including questions on quality of life, treatment decisions, and experiences with cancer care. Survey data will be linked to participant medical record data to achieve study aims.
Conditions Studied
Study Locations (14)
Minnesota
- Allina Health System - Minneapolis
- Mayo Clinic Rochester - Rochester
Florida
- University of Florida - Gainesville
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center Research Institute, Inc - Kansas City
Michigan
- Regents of the University of Michigan - Ann Arbor
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- The Ohio State University - Columbus
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,539 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064150
The ClinicalTrials.gov registry entry for NCT05064150 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,539 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (1838% higher). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 0 interventions.
NCT05064150 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Minnesota, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT05064150 about?
NCT05064150 is a clinical study titled "Neuroendocrine Tumors - Patient Reported Outcomes". With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiven...
What is the current status of trial NCT05064150?
This trial is currently active not recruiting. The enrollment target is 2,539 participants. The study started on 2022-05-10. Estimated completion is 2026-06.
What conditions does trial NCT05064150 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma, Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm.
Who is sponsoring clinical trial NCT05064150?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064150 being conducted?
This trial has 14 study locations across Florida, Iowa, Kansas, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.